HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Tyra Biosciences (NASDAQ:TYRA) and increased the price target from $19 to $23.
March 20, 2024 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tyra Biosciences' Buy rating was reiterated by HC Wainwright & Co., with the price target raised from $19 to $23.
The reiteration of a Buy rating combined with an increased price target typically signals analyst confidence in the company's future performance. This can lead to positive investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100